Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines

Journal of Medical Investigation

Volumn 58, Issue 1-2, 2011, Pages 106-109

  Iwahashi, Shuichi ^a   Ishibashi, Hiroki ^a   Utsunomiya, Tohru ^a   Morine, Yuji ^a   Ochir, Tovuu Lkhaguva ^a   Hanaoka, Jun ^a   Mori, Hiroki ^a   Ikemoto, Tetsuya ^a   Imura, Satoru ^a   Shimada, Mitsuo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Cholangiocarcinoma; Epigenetic regulation; HDAC inhibitor; Pancreas cancer; Valproic acid

Indexed keywords

FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CELL ASSAY; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER;

EID: 79951894022     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: 10.2152/jmi.58.106     Document Type: Article

References (22)

1. Hidalgo M: Pancreatic cancer. N Engl J Med 362: 1605-1617, 2010
2. Cereda S, Passoni P, Reni M, Viganò MG, Aldrighetti L, Nicoletti R, Villa E: The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarci-noma. Cancer 116: 2208-14, 2010
3. Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, Imura S, Ikemoto T: CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol 45: 896-902, 2010
4. Takada T, Kato H, Matsushiro T, Nimura Y, Nagakawa T, Nakayama T: Combination of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 51: 396-400, 1994
5. Kajanti M, Phyronen S: Epirubicin-sequentia methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study. Am J Clin Oncol 17:223-226,1994
6. Haberland M, Montgomery RL, Olson EN: The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat Rev Genet 10: 32-42, 2009
7. Patra SK, Patra A, Dahiya R: Histone deacety-lase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Com-mun 287: 705-713, 2001
8. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811-814, 1998
9. Miyake K, Yoshizumi T, Imura S, Sugimoto K, Batmunkh E, Kanemura H, Morine Y, Shimada M: Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 36: e1-9, 2008
10. Minucci S, Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51, 2006
11. Glozak MA, Seto E: Histone deacetylases and cancer. Oncogene 26: 5420-5432, 2007
12. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978, 2001
13. Xia Q, Sung J, Chowdhury W, Chen CL, Hoti N, Shabbeer S, Carducci M, Rodriguez R: Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 66: 7237-7244, 2006
14. Flis S, Gnyszka A, Flis K, Splawinski J: MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells. Eur J Pharmacol 627: 26-32, 2010
15. Noro R, Miyanaga A, Minegishi Y, Okano T, Seike M, Soeno C, Kataoka K, Matsuda K, Yoshimura A, Gemma A: Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down- regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression. Cancer Sci 101: 1424-1430, 2010
16. Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90: 1621-1625, 1998
17. Blaheta RA, Michaelis M, Driever PH, Cinatl J, Jr: Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 25: 383-397, 2005
18. Tatsumi K, Fukushima M, Shirasaka T, Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78: 748-755, 1987
19. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M: Antitu-mor activity of 1 M tegafur - 0.4 M 5 - chloro - 2,4 -dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopi-cally implanted into nude rats. Cancer Res 56: 2602-2606, 1996
20. Suzuki M, Sekiguchi I, Sato I, Shirasaka T: Development of a novel form of an oral 5-fl uorouracil derivative (S-1) directed to the po-tentiation of the tumor selective cytotoxicity of 5-fl uorouracil by two biochemical modulators. Anticancer Drugs 7: 548-757, 1996
21. Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A: Phase I Trial of Histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and transla-tional study. J Clin Oncol 25: 1979-1985, 2007
22. Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D: Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 15: 2488-2496, 2009